I have been a lecturer in the Section of Molecular Virology at Imperial College London since September 2012. My research programme takes a genetic approach to explore the mechanisms by which Epstein-Barr virus (EBV) establishes latency, and to investigate the intersection between EBV diversity, mutation and pathogenesis. I was previously a postdoc in Professor Martin Allday's group investigating the role of the Epstein-Barr virus EBNA3 proteins in the transformation of B-cells and oncogenesis. I completed my PhD in Oxford in 2000, and then studied Herpesvirus Saimiri with Professor Adrian Whitehouse at the University of Leeds before moving to Imperial in 2003.
Regulation of the host cell transcriptome by EBV.
We (and others) have previously generated genetic mutants of the EBV nuclear antigens (EBNAs) 3A, 3B, 3C and 2. Our transcriptomic analyses of cell lines carrying these genetic variants is available at www.epstein-barrvirus.org.uk. These data are a searchable by gene name, with the intention of allowing other researchers to explore our data, to identify EBV gene products that may influence phenomena they observe. Future data sets will be added as they are published or deemed non-confidential.
This resource is intended to be open for the research community, and anyone wishing to have their data added should contact me, and I will endeavour to do add it, subject to the limitations of my website programming skills.
I do not currently have any positions availabale. Any individuals interested in joining my lab should contact me as far in advance as possible in case there is an opportunity to include you in a funding application.
Enquiries from prospective students with independent funding (or with the potential to obtain such funding) are welcomed at any time. Funded PhD opportunities are available through schemes operated at a college-wide level, such as the Wellcome Trust-funded 'Molecular and cellular basis of infection' PhD scheme, the MRC scheme (operated centrally by Imperial College Faculty of Medicine), the BBSRC-DTP scheme, and the College-funded PhD studentship programme. Note that the BBSRC and MRC schemes are fully funded only for British citizens, while the Wellcome Trust and Imperial schemes are currently funded only for Home/EU fees. Schemes typically take applications annually around November-January to begin in the following September/October. Other possible sources of funding are described here.
Allday MJ, Bazot Q, White RE, 2015, The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells, Epstein Barr Virus, Vol 2: One Herpes Virus: Many Diseases, Vol:391, ISSN:0070-217X, Pages:61-117
et al., 2015, Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types and Normal Infection, Journal of Virology, Vol:89, ISSN:0022-538X, Pages:5222-5237
et al., 2013, Induction of p16(INK4a) Is the Major Barrier to Proliferation when Epstein-Barr Virus (EBV) Transforms Primary B Cells into Lymphoblastoid Cell Lines, Plos Pathogens, Vol:9, ISSN:1553-7374
et al., 2012, BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV, Nucleic Acids Research, Vol:40, ISSN:0305-1048, Pages:7233-7246
et al., 2012, EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors, Journal of Clinical Investigation, Vol:122, ISSN:0021-9738, Pages:1487-1502